- World rank, all time
- #25,289 of 42,892
- Rank in United States
- #5,410 of 8,685
- Research works
- 152 ◆ 2% vs 2013–17
- Citations
- 4.6k 30.2 per fractional work
- Top-10% rate
- 12.3% record average 16.5%
- Open access
- 32% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.5×. Every wedge is a field page.
- Immunology and Microbiology 6.5×
- Biochemistry, Genetics and Molecular Biology 4.5×
- Medicine 3.3×
- Pharmacology, Toxicology and Pharmaceutics 0.8×
- Neuroscience 0.7×
- Business, Management and Accounting 0.4×
- Dentistry 0.4×
- Mathematics 0.2×
- Chemistry 0.2×
- Materials Science 0.1×
- Health Professions 0.1×
- Engineering 0.1×
- Environmental Science 0.0×
Who are the top researchers at Mary Crowley Cancer Research Center?
Ranked on the composite score, Neil Senzer, John Nemunaitis and Minal Barve lead among researchers whose main affiliation is Mary Crowley Cancer Research Center.
- 1 Neil Senzer United States · #160,712 worldwide 132 citations · 32 works
- 2 John Nemunaitis United States · #217,692 worldwide 447 citations · 122 works
- 3 Minal Barve United States · #362,378 worldwide 129 citations · 51 works
- 4 James Strauss United States · #1,552,582 worldwide 6 citations · 20 works
- 5 Casey Cunningham United States · #1,568,765 worldwide 17 citations · 15 works
Which keywords describe research at Mary Crowley Cancer Research Center?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Tumor Microenvironment, Targeted Therapy, Breast Cancer, Clinical Trials, Cancer Therapy and Tumor Regression.
- Glycosylation
- Palbociclib
- Metastasis
- Genomic Instability
- CDK4/6 Inhibitors
- Arginine Deprivation
- PET Imaging
- Metastatic
- EGFR Mutations
- ALK Inhibitors
- Genomic Profiling
- Metastatic Breast Cancer
- PD-1 and PD-L1
- Tumor Regression
- Clinical Trials
- Tumor Microenvironment
- Immunotherapy
- Chemotherapy
- Targeted Therapy
- Breast Cancer
- Cancer Therapy
- Immune Checkpoint Blockade
- Cancer Immunotherapy
- Gene Therapy
- Tumor Targeting
- Cancer
- Lymphoma
- Monoclonal Antibody
- Trastuzumab
- Bacterial Therapy
- EGFR
- HER2
- Monoclonal Antibodies
- Precision Medicine
- Molecular Subtypes
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 35 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 35 words, with their numbers
- Chemotherapy4▲ 23×11 topics
- Immunotherapy3▲ 19×12 topics
- Targeted Therapy3▲ 55×5 topics
- Tumor Microenvironment3▲ 27×6 topics
- Breast Cancer2▲ 41×4 topics
- Clinical Trials2▲ 14×5 topics
- Cancer Therapy2▲ 16×10 topics
- Tumor Regression2▲ 74×2 topics
- Immune Checkpoint Blockade2▲ 65×1 topic
- PD-1 and PD-L12▲ 65×1 topic
- Cancer Immunotherapy2▲ 44×3 topics
- Metastatic Breast Cancer2▲ 111×2 topics
- Gene Therapy1▲ 32×3 topics
- Genomic Profiling1▲ 58×2 topics
- Tumor Targeting1▲ 30×3 topics
- ALK Inhibitors1▲ 85×1 topic
- Cancer1▲ 3.8×12 topics
- EGFR Mutations1▲ 85×1 topic
- Lymphoma1▲ 30×2 topics
- Metastatic1▲ 81×2 topics
- Monoclonal Antibody1▲ 99×2 topics
- PET Imaging1▲ 29×4 topics
- Trastuzumab1▲ 108×2 topics
- Arginine Deprivation1▲ 127×1 topic
- Bacterial Therapy1▲ 127×1 topic
- CDK4/6 Inhibitors1▲ 182×1 topic
- EGFR1▲ 169×1 topic
- Genomic Instability1▲ 41×2 topics
- HER21▲ 169×1 topic
- Metastasis1▲ 13×6 topics
- Monoclonal Antibodies1▲ 52×2 topics
- Palbociclib1▲ 182×1 topic
- Precision Medicine1▲ 9.8×3 topics
- Glycosylation1▲ 39×2 topics
- Molecular Subtypes1▲ 52×2 topics
Which research topics does Mary Crowley Cancer Research Center publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research and Cancer Research and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 3 HER2/EGFR in Cancer Research Oncology 1 works
- 4 Cancer Research and Treatments Biotechnology 1 works
- 5 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 6 Colorectal Cancer Treatments and Studies Oncology 1 works
- 7 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 8 CAR-T cell therapy research Oncology 1 works
- 9 Cancer Genomics and Diagnostics Cancer Research 1 works
- 10 PARP inhibition in cancer therapy Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Mary Crowley Cancer Research Center's research output changed?
Output in 2018–2022 was 2% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Dallas
- The University of Texas Southwestern Medical Center
- Southern Methodist University
- Texas Instruments (United States)
- Baylor University Medical Center
- Lung Institute
- University of Texas Health Science Center at Dallas
- Jacobs (United States)
- Texas Health Dallas
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.